| Literature DB >> 33364209 |
Abbasian Ardakani A1, Sattar A R2, Abolghasemi J3, Mohammadi A2.
Abstract
BACKGROUND: The ability to monitor kidney function after transplantation is one of the major factors to improve care of patients.Entities:
Keywords: Computer-Assisted; Decision Making; Kidney Transplantation; Pattern Recognition System; Ultrasonography
Year: 2020 PMID: 33364209 PMCID: PMC7753263 DOI: 10.31661/jbpe.v0i0.928
Source DB: PubMed Journal: J Biomed Phys Eng ISSN: 2251-7200
Figure 1Overview of computer-aided diagnosis (CAD) process in the ultrasound kidney images
Demographic characteristics and laboratory data of patients before and at follow-up.
| Increased Group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI (Kg/m2) | Obesity Class | Gender Before Follow-Up | Total | Age (Mean±SD) | Creatinine (Mean±SD) | Gender after 3 years Follow-Up | Total | Age (Mean±SD) | Creatinine (Mean±SD) | |||
| Male | Female | Male | Female | |||||||||
| Underweight | < 18.5 | 1 | - | 1 | 26 | 1.25 | 1 | - | 1 | 26 | 3.8 | |
| Normal | 18.5–24.9 | 14 | 4 | 18 | 40.84±14.63 | 2.29±1.01 | 15 | 3 | 18 | 33.09±11.82 | 3.88±1.86 | |
| Overweight | 25.0–29.9 | 2 | 1 | 3 | 42.67±22.48 | 1.68±0.11 | 1 | 2 | 3 | 49.2±11.77 | 7.32±1.74 | |
| Obesity | 30.0–34.9 | I | - | 1 | 1 | 51 | 2.38 | - | 1 | 1 | 51 | 5.5 |
| 35.0–39.9 | II | - | - | - | - | - | - | - | - | - | - | |
| Extreme Obesity | 40.0 + | III | - | - | - | - | - | - | - | - | - | - |
| Underweight | < 18.5 | - | - | - | - | - | 2 | - | 2 | 23±6 | 2.6±0.5 | |
| Normal | 18.5–24.9 | 11 | 3 | 14 | 34.85±14.86 | 3.85±1.57 | 8 | 3 | 11 | 34.64±13.67 | 2.98±1.37 | |
| Overweight | 25.0–29.9 | - | 1 | 1 | 27 | 5.2 | 1 | 2 | 3 | 46.67±14.38 | 2.5±0.37 | |
| Obesity | 30.0–34.9 | I | - | 2 | 2 | 50.5±1.5 | 2.38 | - | 1 | 1 | 49 | 1.63 |
| 35.0–39.9 | II | - | - | - | - | - | - | - | - | - | - | |
| Extreme Obesity | 40.0 + | III | - | - | - | - | - | - | - | - | - | - |
BMI = Body mass index
Figure 2Diagram to report flow of participants through the study.
Correlations between serum creatinine (sCr) level and run-length matrix feature in three normalization schemes for decreased group before and at follow-up.
| Normalization | Texture Feature | Correlation Coefficient (P-value) | Paired-Samples T Test (P-value) | |
|---|---|---|---|---|
| Horz_GLNU | -0.881 (<0.001) | 0.003 | 0.657 (0.470, 0.845) | |
| Vert_GLNU | -0.894 (<0.001) | 0.003 | 0.671 (0.486, 0.856) | |
| Vert_RLNU | -0.843 (<0.001) | 0.043 | 0.616 (0.425, 0.807) | |
| 45Dgr_GLNU | -0.886 (<0.001) | 0.004 | 0.661 (0.473, 0.848) | |
| 135Dgr_GLNU | -0.889 (<0.001) | 0.005 | 0.664 (0.478, 0.851) | |
| Horz_RLNU | 0.693 (<0.001) | 0.003 | 0.882 (0.770, 0.995) | |
| Horz_GLNU | -0.823 (<0.001) | <0.001 | 0.834 (0.700, 0.967) | |
| Horz_LRE | -0.815 (<0.001) | <0.001 | 0.678 (0.479, 0.877) | |
| Horz_SRE | 0.828 (<0.001) | <0.001 | 0.699 (0.508, 0.890) | |
| Horz_Fraction | 0.824 (<0.001) | <0.001 | 0.692 (0.498, 0.886) | |
| Vert_RLNU | -0.571 (<0.001) | 0.037 | 0.619 (0.398, 0.841) | |
| Vert_GLNU | -0.829 (<0.001) | <0.001 | 0.761 (0.595, 0.927) | |
| Vert_LRE | -0.762 (<0.001) | <0.001 | 0.730 (0.548, 0.913) | |
| Vert_SRE | 0.760 (<0.001) | <0.001 | 0.751 (0.578, 0.923) | |
| Vert_Fraction | 0.756 (<0.001) | <0.001 | 0.744 (0.568, 0.920) | |
| 45Dgr_GLNU | -0.826 (<0.001) | <0.001 | 0.758 (0.590, 0.926) | |
| 45Dgr_LRE | -0.875 (<0.001) | <0.001 | 0.692 (0.498, 0.886) | |
| 45Dgr_SRE | 0.875 (<0.001) | <0.001 | 0.723 (0.542, 0.905) | |
| 45Dgr_Fraction | 0.881 (<0.001) | <0.001 | 0.702 (0.513, 0.892) | |
| 135Dgr_GLNU | -0.829 (<0.001) | <0.001 | 0.761 (0.595, 0.927) | |
| 135Dgr_LRE | -0.878 (<0.001) | <0.001 | 0.706 (0.518, 0.894) | |
| 135Dgr_SRE | 0.898 (<0.001) | <0.001 | 0.706 (0.517, 0.894) | |
| 135Dgr_Fraction | 0.878 (<0.001) | <0.001 | 0.713 (0.527, 0.898) | |
| Horz_GLNU | -0.792 (<0.001) | <0.001 | 0.727 (0.553, 0.900) | |
| Horz_LRE | -0.879 (<0.001) | 0.001 | 0.626 (0.412, 0.841) | |
| Vert_GLNU | -0.796 (<0.001) | <0.001 | 0.709 (0.529, 0.889) | |
| Vert_LRE | -0.569 (<0.001) | <0.001 | 0.592 (0.381, 0.803) | |
| Vert_SRE | 0.635 (<0.001) | <0.001 | 0.595 (0.389, 0.801) | |
| 45Dgr_GLNU | -0.749 (<0.001) | <0.001 | 0.713 (0.534, 0.892) | |
| 135Dgr_GLNU | -0.797 (<0.001) | <0.001 | 0.713 (0.534, 0.892) |
Az value was obtained with 95% confidence intervals.
Correlations between serum creatinine (sCr) level and run-length matrix feature in three normalization schemes for increased group before and at follow-up.
| Texture Feature Group | Texture Feature | Correlation Coefficient (P-value) | Paired-Samples T Test (P-value) | |
|---|---|---|---|---|
| Horz_RLNU | 0.364 (0.017) | 0.001 | 0.779 (0.643, 0.914) | |
| Horz_GLNU | -0.580 (0.027) | <0.001 | 0.853 (0.736, 0.969) | |
| Vert_RLNU | 0.832 (0.038) | <0.001 | 0.932 (0.864, 1.000) | |
| Vert_GLNU | -0.209 (0.004) | <0.001 | 0.866 (0.754, 0.978) | |
| 45Dgr_RLNU | 0.500 (0.014) | <0.001 | 0.915 (0.838, 0.992) | |
| 45Dgr_GLNU | -0.182 (0.022) | <0.001 | 0.851 (0.729, 0.972) | |
| 135Dgr_RLNU | 0.550 (0.001) | <0.001 | 0.926 (0.854, 0.998) | |
| 135Dgr_GLNU | -0.372 (0.015) | <0.001 | 0.856 (0.739, 0.973) | |
| Horz_RLNU | -0.192 (0.002) | <0.001 | 0.875 (0.776, 0.974) | |
| Horz_GLNU | 0.316 (0.038) | <0.001 | 0.877 (0.777, 0.977) | |
| Vert_RLNU | -0.711 (0.004) | <0.001 | 0.924 (0.852, 0.997) | |
| Vert_GLNU | 0.630 (0.003) | <0.001 | 0.879 (0.783, 0.975) | |
| Vert_LRE | 0.670 (<0.001) | 0.049 | 0.626 (0.459, 0.792) | |
| Vert_Fraction | -0.676 (<0.001) | 0.040 | 0.631 (0.465, 0.798) | |
| 45Dgr_RLNU | -0.243 (0.018) | <0.001 | 0.909 (0.829, 0.990) | |
| 45Dgr_GLNU | 0.545 (0.042) | <0.001 | 0.870 (0.769, 0.970) | |
| 135Dgr_RLNU | -0.579 (0.005) | <0.001 | 0.921 (0.846, 0.995) | |
| 135Dgr_GLNU | 0.513 (0.009) | <0.001 | 0.871 (0.772, 0.971) | |
| 135Dgr_LRE | 0.696 (<0.001) | 0.028 | 0.635 (0.469, 0.802) | |
| 135Dgr_SRE | -0.697 (<0.001) | 0.035 | 0.626 (0.456, 0.795) | |
| 135Dgr_Fraction | -0.699 (<0.001) | 0.027 | 0.629 (0.461, 0.798) | |
| Horz_GLNU | -0.693 (0.012) | <0.001 | 0.896 (0.804, 0.988) | |
| Horz_LRE | 0.287 (0.035) | 0.001 | 0.709 (0.557, 0.861) | |
| Vert_GLNU | 0.744 (0.013) | <0.001 | 0.900 (0.808, 0.992) | |
| Vert_LRE | 0.456 (0.001) | <0.001 | 0.531 (0.359, 0.703) | |
| Vert_SRE | -0.460 (0.001) | <0.001 | 0.507 (0.337, 0.676) | |
| 45Dgr_GLNU | 0.388 (0.010) | <0.001 | 0.892 (0.794, 0.990) | |
| 135Dgr_GLNU | 0.765 (0.016) | <0.001 | 0.900 (0.805, 0.994) |
Az value was obtained with 95% confidence intervals.
Correlations between serum creatinine (sCr) level and run-length matrix feature in three normalization schemes for decreased group before and at follow-up.
| Normalization | Method of feature reduction | a SEN (%) | a SPC (%) | ACC (%) | a PPV (%) | a NPV (%) | a Az value | Correct classification |
|---|---|---|---|---|---|---|---|---|
| NS. PCA | 47.06 (32.03, 77.08) | 41.18 (34.83, 87.14) | 44.12 | 44.43 (07.66, 81.2) | 43.75 (03.61, 83.89) | 0.484 (0.282, 0.686) | 15/34 [44.18%] | |
| S. PCA | 58.82 (41.18, 82.35) | 64.70 (62.47, 8154) | 61.76 | 62.50 (39.55, 85.45) | 61.10 (41.60, 80.60) | 0.657 (0.465, 0.849) | 21/34 [61.76%] | |
| NS. LDA | 82.35 (64.71, 100) | 88.23 (67.50, 100) | 85.29 | 87.50 (74.49, 100) | 83.30 (66.73, 99.87) | 0.927 (0.840, 1.000) | 29/34 [85.29%] | |
| S. LDA | 82.35 (64.71, 100) | 88.23 (67.50, 1.00) | 85.29 | 87.50 (74.49, 100) | 83.30 (66.73, 99.87) | 0.927 (0.840, 1.000) | 29/34 [85.29%] | |
| NS. PCA | 88.23 (47.06, 100) | 88.23 (67.50, 100) | 88.23 | 88.23 (76.16, 100) | 88.23 (63.10, 100) | 0.938 (0.863, 1.000) | 30/34 [88.23%] | |
| S. PCA | 94.12 (82.35, 100) | 88.23 (76.47, 100) | 91.18 | 88.89 (77.70, 100) | 93.75 (42.25, 100) | 0.962 (0.906, 1.000) | 31/34 [91.18%] | |
| NS. LDA | 100 | 100 | 100 | 100 | 100 | 1 | 34/34 [100%] | |
| S. LDA | 100 | 100 | 100 | 100 | 100 | 1 | 34/34 [100%] | |
| NS. PCA | 52.94 (17.65, 94.12) | 41.18 (29.94, 74.26) | 47.06 | 47.37 (10.56, 84.18) | 46.67 (11.09, 82.25) | 0.505 (0.306, 0.705) | 16/34 [47.06%] | |
| S. PCA | 70.59 (40.88, 94.12) | 88.23 (64.71, 100) | 79.41 | 85.71 (70.56, 100) | 75 (64.82, 85.18) | 0.841 (0.706, 0.976) | 27/34 [79.41%] | |
| NS. LDA | 94.12 (61.62, 100) | 82.35 (73.38, 100) | 88.23 | 84.21 (76.53, 91.89) | 93.33 (85.81, 100) | 0.934 (0.856, 1.000) | 30/34 [88.23%] | |
| S. LDA | 94.12 (61.62, 100) | 82.35 (73.38, 100) | 88.23 | 84.21 (76.53, 91.89) | 93.33 (85.81, 100) | 0.934 (0.856, 1.000) | 30/34 [88.23%] |
SEN = sensitivity; SPC = specificity; ACC = accuracy; PPV = positive predictive value; NPV = negative predictive value; Az= area under ROC curve; a: Numbers in parentheses are 95% confidence intervals.
Diagnostic performance of proposed method in three normalization schemes for increased creatinine group.
| Normalization | Method of feature reduction | a SEN (%) | a SPC (%) | ACC (%) | a PPV (%) | a NPV (%) | a Az value | Correct classification |
|---|---|---|---|---|---|---|---|---|
| NS. PCA | 65.22 (48.54, 86.36) | 73.91 (58.01, 94.75) | 69.56 | 71.43 (51.68, 91.18) | 68.00 (57.30, 78.70) | 0.750 (0.607, 0.894) | 32/46 [69.56%] | |
| S. PCA | 69.56 (39.18, 87.26) | 78.26 (61.37, 94.89) | 73.91 | 76.19 (60.18, 92.20) | 72.00 (61.72, 82.28) | 0.798 (0.668, 0.928) | 34/46 [73.91%] | |
| NS. LDA | 86.96 (79.27, 94.79) | 91.30 (87.94, 100) | 89.13 | 90.90 (81.25, 100) | 87.50 (75.49, 99.51) | 0.949 (0.893, 1.000) | 41/46 [89.13%] | |
| S. LDA | 86.96 (79.27, 94.79) | 91.30 (87.94, 100) | 89.13 | 90.90 (81.25, 100) | 87.50 (75.49, 99.51) | 0.949 (0.893, 1.000) | 41/46 [89.13%] | |
| NS. PCA | 78.26 (58.82, 97.21) | 69.56 (35.29, 94.12) | 73.91 | 72 (53.51, 90.49) | 76.19 (54.86, 97.52) | 0.790 (0.65,0.93) | 34/46 [73.91%] | |
| S. PCA | 78.26 (63.38, 88.96) | 78.26 (54.18, 92.22) | 78.26 | 78.26 (64.33, 92.19) | 78.26 (63.73, 92.79) | 0.828 (0.701, 0.955) | 36/46 [78.26%] | |
| NS. LDA | 95.65 (76.35, 100) | 91.3 (70.66, 100) | 93.47 | 91.67 (83.22, 100) | 95.45 (56.81, 100) | 0.974 (0.936, 1.000) | 43/46 [93.48%] | |
| NS. LDA | 95.65 (76.35, 100) | 91.3 (70.66, 100) | 93.47 | 91.67 (83.22, 100) | 95.45 (56.81, 100) | 0.974 (0.936, 1.000) | 43/46 [93.48%] | |
| NS. PCA | 65.22 (35.00, 82.35) | 69.56 (26.32, 94.12) | 67.39 | 68.18 (45.52, 90.84) | 66.67 (53.99, 79.35) | 0.743 (0.596, 0.89) | 31/46 [67.39%] | |
| S. PCA | 82.61 (67.50, 100) | 73.91 (70.59, 100) | 78.26 | 76 (61.38, 90.62) | 80.95 (58.43, 100) | 0.830 (0.712, 0.948) | 36/46 [78.26%] | |
| NS. LDA | 91.3 (85.02, 100) | 82.61 (81.21, 88.90) | 86.96 | 84 (76.11, 91.89) | 90.48 (59.51, 100) | 0.934 (0.867, 1.000) | 40/46 [86.97%] | |
| S. LDA | 91.3 | 82.61 | 86.96 | 84 | 90.48 | 0.934 (0.867, 1.000) | 40/46 [86.97%] |
SEN = sensitivity; SPC = specificity; ACC = accuracy; PPV = positive predictive value; NPV = negative predictive value; Az= area under ROC curve; a: Numbers in parentheses are 95% confidence intervals.
Figure 3Sample distributions for the best results after texture analysis method, linear discriminant analysis (LDA): 3sigma normalization for decreased group (A) and for increased group (B). Most discriminating features (MDF); “1” and “2” represent patients before and after follow-up, respectively.
Figure 4The diagrams of the receiver operating characteristic (ROC) curve for each texture analysis method in default: (A) decreased group; (B) increased group.
Figure 5The diagrams of the receiver operating characteristic (ROC) curve for each texture analysis method in 3sigma normalization: (A) decreased group; (B) increased group.
Figure 6The diagrams of the receiver operating characteristic (ROC) curve for each texture analysis method in 1-99% normalization: (A) decreased group; (B) increased group.